Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis

Renal AA amyloidosis is the most severe type of renal pathology in patients with ankylosing spondylitis (AS). The characteristic symptoms of AA amyloidosis in rheumatic diseases do not often occur for years, making it difficult to diagnose it early and to start adequate therapy.Objective: to identify the clinical features of AS complicated by secondary AA amyloidosis.Patients and methods. The investigation enrolled 9 patients with AS (according to the 1984 modified New York criteria) and histologically confirmed secondary AA amyloidosis (Group 1). A comparison group included 216 AS patients without amyloidosis (Group 2).Results and discussion. In Group 1 patients, the age at the onset of AS was significantly less and the disease duration was 4 times longer than those in Group 2. All the patients with AA amyloidosis had enthesitis and arthritis, including those of the hip joints. The scores of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), and the acute phase inflammation index CRP were higher in Group 1 than in Group 2.Conclusion. The clinical feature of AS complicated by secondary AA-amyloidosis is the long duration of the disease and the high frequency of juvenile onset, non-axial manifestations (arthritis, coxitis and enteritis), as well as the high activity of systemic inflammation.

Download Full-text

AB0719 CLINICAL FEATURES OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND SECONDARY AA-AMYLOIDOSIS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.3209 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1654.2-1655

Author(s):

D. Rumiantceva ◽

E. Agafonova ◽

S. Krasnenko ◽

M. Podryadnova ◽

A. Starkova ◽

...

Keyword(s):

New York ◽

Ankylosing Spondylitis ◽

Clinical Features ◽

Disease Duration ◽

Hla B27 ◽

Aa Amyloidosis ◽

Bowel Diseases ◽

Male Patients ◽

Group 2 ◽

Group 1

Background:Secondary AA-amyloidosis is one of the most serious complications of ankylosing spondylitis (AS). Better knowledge of specific to secondary AA-amyloidosis clinical features is important for improving further management of these patients.Objectives:To conduct a comparative analysis of AS patients with and without secondary AA-amyloidosis.Methods:The study included 220 AS patients (according to modified New York criteria) without amyloidosis - Group 1, and 9 AS patients with histologically confirmed secondary AA-amyloidosis – Group 2.Results:Table 1 presents the comparative characteristics of Group 1 and Group 2 patients. Both groups were comparable in terms of patients’ age, rates of HLA B27 positivity, presence of enthesitis, uveitis, inflammatory bowel diseases (IBD), and psoriasis on assessment. Group 2 patients tended to be younger at AS onset, while shorter disease duration and fewer male patients were established for Group 1. Group 2 had higher rates of extra-spinal AS manifestations, such as arthritis and coxitis. It should be noted that all AS patients with secondary AA-amyloidosis were males, with clinically manifest arthritis, involving hip joints, and AS onset in the childhood in 8 out of 9 cases.Table 1.Comparative characteristics of Group 1 and Group 2 AS patients.Group 1 (n=220)Group 2 (n=9)рMean age, M±α, y.35,1±9,540,1±8,6>0.05Mean age at the onset, M±α, y.29,9±9,613,4±7,5<0.05Mean disease duration, M±α, y.6,9±5,626,3±6,5<0.05Men, n (%)162 (73,6%)9 (100%)<0.05HLA B27, n (%)202 (91,8%)9 (100%)>0.05Arthritis, n (%)182 (82,7%)9 (100%)<0.05Coxitis, n (%)119 (54,0%)9 (100%)<0.05Enthesitis, n (%)105 (47,7%)7 (78%)>0.05Uveitis, n (%)52 (23,6%)4 (44,4%)>0.05IBD, n (%)5 (2,2%)0>0.05Psoriasis, n (%)24 (10,9%)0>0.05Conclusion:Patients with AS and secondary AA amyloidosis are predominantly of male gender, who usually get sick in childhood, have 100% HLA-B27 positivity, peripheral arthritis, and coxitis.Disclosure of Interests:None declared

Download Full-text

Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis

The Journal of Rheumatology ◽

10.3899/jrheum.090476 ◽

2010 ◽

Vol 37 (4) ◽

pp. 829-834 ◽

Cited By ~ 29

Author(s):

TAMAR F. BRIONEZ ◽

SHERVIN ASSASSI ◽

JOHN D. REVEILLE ◽

CHARLES GREEN ◽

THOMAS LEARCH ◽

...

Keyword(s):

New York ◽

Ankylosing Spondylitis ◽

Disease Activity ◽

Activity Index ◽

Disease Activity Index ◽

Multivariate Regression Analysis ◽

Passive Coping ◽

Psychological Variables ◽

Psychological Measures

Objective.To investigate the role of psychological variables in self-reported disease activity in patients with ankylosing spondylitis (AS), while controlling for demographic and medical variables.Methods.Patients with AS (n = 294) meeting modified New York criteria completed psychological measures evaluating depression, resilience, active and passive coping, internality, and helplessness. Demographic, clinical, and radiologic data were also collected. Univariate and multivariate analyses were completed to determine the strength of the correlation of psychological variables with disease activity, as measured by the Bath AS Disease Activity Index (BASDAI).Results.In the multivariate regression analysis, the psychological variables contributed significantly to the variance in BASDAI scores, adding an additional 33% to the overall R-square beyond that accounted for by demographic and medical variables (combined R-square 18%). Specifically, arthritis helplessness and depression accounted for the most significant portion of the variance in BASDAI scores in the final model.Conclusion.Arthritis helplessness and depression accounted for significant variability in self-reported disease activity beyond clinical and demographic variables in patients with AS. These findings have important clinical implications in the treatment and monitoring of disease activity in AS, and suggest potential avenues of intervention.

Download Full-text

The Role of Clinical and Ultrasound Enthesitis Scores in Ankylosing Spondylitis

Life ◽

10.3390/life11030218 ◽

2021 ◽

Vol 11 (3) ◽

pp. 218

Author(s):

Alesandra Florescu ◽

Vlad Pădureanu ◽

Dan Nicolae Florescu ◽

Anca Bobircă ◽

Lucian-Mihai Florescu ◽

...

Keyword(s):

New York ◽

Ankylosing Spondylitis ◽

Disease Activity ◽

Activity Index ◽

Disease Activity Index ◽

Clinical Score ◽

Chronic Inflammatory Disease ◽

Joint Involvement ◽

History Of ◽

Research Consortium

Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory disease, part of the spondyloarthritis (SpA) group, characterized by axial (spine and sacroiliac joints), entheseal, and peripheral joint involvement, which is frequently associated with extra-articular manifestations. Material and Methods: The study included a number of 30 patients diagnosed with AS according to the New York modified criteria, with history of entheseal pain, hospitalized between 2016–2018 in the Department of Rheumatology of the Emergency County Hospital of Craiova. Results: Regarding the Belgrade Ultrasound Enthesitis Score (BUSES) score and the disease activity calculated using the Ankylosing Spondylitis Disease Activity Score (ASDAS), they did not show a statistically significant association (p = 0.738). Additionally, BUSES did not have a statistically significant association with the disease activity quantified by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (p = 0.094). The Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC) clinical score was not statistically associated with ASDAS (p = 0.434) nor with BASDAI (p = 0.130). The SPARCC clinical score and the BUSES ultrasound score were statistically significantly associated, registering a value of p = 0.018. Conclusions: Our study proved a significant correlation between SPARCC and BUSES, although in literature the evidence is contrasting.

Download Full-text

Visceral Fat Reflects Disease Activity in Patients with Ankylosing Spondylitis

Clinical & Investigative Medicine ◽

10.25011/cim.v37i3.21385 ◽

2014 ◽

Vol 37 (3) ◽

pp. 186

Author(s):

Mesut Aydin ◽

Fatma Aydin ◽

Murat Yuksel ◽

Abdulkadir Yildiz ◽

Nihat Polat ◽

...

Keyword(s):

New York ◽

Adipose Tissue ◽

Ankylosing Spondylitis ◽

Disease Activity ◽

Visceral Adipose Tissue ◽

Visceral Fat ◽

Activity Index ◽

Disease Activity Index ◽

Infliximab Treatment ◽

Visceral Adipose

Purpose: Response to infliximab treatment diminishes as body mass index (BMI) increases in patients with ankylosing spondylitis (AS). The purpose of the study was to determine if diminished response to infliximab treatment in patients with AS could be associated with increased visceral adipose tissue rather than increased BMI. Methods: Twenty six AS patients (21 males and five females) who fulfilled the modified New York criteria and who were currently receiving infliximab treatment were enrolled in the study. Pain was measured by the visual analogue scale (VAS). The disease activity and functional status were assessed by the Bath AS Disease Activity Index (BASDAI) and the Bath AS Functional Index (BASFI). The Bath AS Metrology Index (BASMI) was used to evaluate mobility restrictions. Weight and visceral body composition were measured without shoes in light indoor clothes using a bio-impedance meter. Results: There was a significant correlation between visceral adipose tissue amount and disease activity under infliximab treatment. In correlation analysis, visceral fat showed significant correlations between BASDAI (r=0.545, p=0.004) and VAS (r=0.458, p=0.019). Total body fat also showed a significant correlation with BASDAI (r=0.463, p=0.017). Conclusion: A significant correlation was found between visceral adipose tissue amount and disease activity in patients with AS.

Download Full-text

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis

The Journal of Rheumatology ◽

10.3899/jrheum.181040 ◽

2019 ◽

Vol 47 (1) ◽

pp. 35-41 ◽

Cited By ~ 2

Author(s):

Jürgen Braun ◽

Xenofon Baraliakos ◽

Uta Kiltz ◽

Klaus Krüger ◽

Gerd R. Burmester ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Tumor Necrosis Factor ◽

Disease Activity ◽

Tumor Necrosis ◽

Activity Index ◽

Tumor Necrosis Factor Inhibitor ◽

Disease Activity Index ◽

Factor Inhibitor ◽

Group 2 ◽

Necrosis Factor

Objective.International recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) recommend a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) level of disease activity of ≥ 4 to initiate treatment with biologics. We aimed to evaluate the level of disease activity used to initiate tumor necrosis factor inhibitor (TNFi) treatment and the level of responses to treatment based on different BASDAI cutoffs.Methods.This is a posthoc analysis of the noninterventional, prospective, GO-NICE study in the subgroup of biologic-naive AS treated with golimumab (GOL) 50 mg subcutaneously once monthly.Results.Of the 244 biologic-naive AS patients at baseline, 70.5% had a BASDAI ≥ 4 (Group 1), 14.3% had 2.8 to < 4 (Group 2), and 15.2% had even < 2.8 (Group 3). A total of 134 patients (54.9%) completed the 24-month observational period. The mean BASDAI in Groups 1, 2, and 3 was initially 5.9 ± 1.3, 3.4 ± 0.4, and 2.0 ± 0.8, decreased to 2.2 ± 2.0, 1.9 ± 1.2, and 1.0 ± 1.2 within 3 months (all p < 0.0001 vs baseline), and decreased significantly to 2.2 ± 1.7, 1.9 ± 1.7, and 1.4 ± 1.0 at Month 24 (all p < 0.005), respectively. BASDAI 50% improvement was noted in 68.8%, 44.8%, and 45.2% of patients at Month 3, and in 84.9%, 61.9%, and 55.0% at Month 24.Conclusion.TNFi treatment was initiated in almost a third of AS patients with lower disease activity states as assessed by BASDAI cutoff of ≥ 4. Patients with a BASDAI between 2.8 and < 4 appeared to benefit significantly from GOL treatment, while patients with BASDAI < 2.8 did not. This finding should lead to a reevaluation of the established BASDAI cutoff of ≥ 4.

Download Full-text

P185 Does BASDAI score correlate to MRI changes in ankylosing spondylarthritis?

Rheumatology ◽

10.1093/rheumatology/keab247.180 ◽

2021 ◽

Vol 60 (Supplement_1) ◽

Author(s):

Nibha Jain ◽

Swetha Byravan Byravan ◽

Jenna Stairs ◽

Winston Rennie ◽

Moorthy Arumugam

Keyword(s):

Back Pain ◽

Ankylosing Spondylitis ◽

Disease Activity ◽

Clinical Features ◽

Activity Index ◽

Outcome Measurement ◽

Disease Activity Index ◽

Inflammatory Back Pain ◽

Hla B27 ◽

Mri Changes

Abstract Background/Aims The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is routinely used subjective outcome measurement of disease activity in Ankylosing Spondylitis (AS). BASDAI > 4 is used as a criterion for commencing anti-TNF therapy. Previous studies shown BASDAI correlation with MRI has been proven to be weak. We did this study to systemically compare clinical and radiological data of patients with AS and to look for the degree of correlation between BASDAI score and MRI changes positive for spondyloarthritis in our cohort of patients. Methods A retrospective analysis of AS patients attending Leicester spondylarthritis service at University Hospitals Leicester Trust (UHL) was carried out. Clinical characteristics such as HLA-B27 status, extra-articular features, family history of AS and CRP measurement were obtained from online systems and clinic letters. Online records were reviewed to see if patients had a MRI of the sacroiliac joints along with a BASDAI score at the time of MRI. Medcalc calculator was used for statistical analysis. Results A total of 106 patients were analysed with a mean age of 45.6 +/- 11.6 years (M = 62, F = 44) with mean BASDAI of 5.0 +/- 2.5. Mean CRP was 17.01+/- 30.4 (median CRP 6.5). 61% (n = 65) were HLA-B27 positive. 70 of 106 patients had a sacroiliac MRI scan which could be reviewed to a satisfactory level to determine whether disease is present or not. Two results were statistically significant when comparing active versus no active lesions on MRI: inflammatory back pain and anti-TNF therapy (Table 1). P185 Table 1:Comparison of clinical features in patients with active versus inactive lesions on MRI sacroiliac joint.Active lesions on MRI N = 45No active lesions on MRI N = 25P valueMean BASDAI (SD)5.0 (2.6)5.4(2.6)0.5Mean ASDAS CRP (SD)2.14(1.1)2.04(0.6)0.73Mean CRP (SD) mg/l14.7(21)17.8(33)0.645.5HLA-B2731180.Uveitis1190.3Inflammatory back pain40170.03Enthesitis820.3Peripheral Arthritis670.1Dactylitis010.2Psoriasis211Inflammatory bowel disease710.1Ethnicity: Caucasian37230.2Ethnicity: Asian820.3Age45.5 (10.2)50.5(11.3)0.06M: F26:1916:90.7Anti-TNF therapy1840.03BASDAI >428150.8BASDAI <417100.8BASDAI= Bath ankylosing spondylitis disease activity index, ASDAS= Ankylosing Spondylitis disease. CRP=C-reactive protein, HLA= human leucocyte antigen. Conclusion BASDAI score did not statistically correlate with the severity of inflammation as objectively observed on MRI. Only inflammatory back pain and anti-TNF therapy correlated with MRI disease activity. There was no difference in clinical features including HLA-B27 between patients with active and inactive MRI. Thus, BASDAI as a criterion for biologic therapy may need re-considering. Disclosure N. Jain: None. S. Byravan: None. J. Stairs: None. W. Rennie: None. M. Arumugam: Other; Speaker and Conference Fee MSD, Novartis, Abbvie.

Download Full-text

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study

Annals of the Rheumatic Diseases ◽

10.1136/ard.2011.154799 ◽

2011 ◽

Vol 71 (5) ◽

pp. 661-667 ◽

Cited By ~ 69

Author(s):

Jürgen Braun ◽

Atul Deodhar ◽

Robert D Inman ◽

Désirée van der Heijde ◽

Michael Mack ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Safety Profile ◽

Activity Index ◽

Disease Activity Index ◽

Subcutaneous Injections ◽

Treatment Regimens ◽

Group 3 ◽

Group 2 ◽

Necrosis Factor ◽

Group 1

ObjectiveTo assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis.MethodsAt baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week 16, patients in groups 1 and 2 with <20% improvement in total back pain and morning stiffness entered early escape to 50 or 100 mg, respectively. At week 24, patients still receiving placebo crossed over to golimumab 50 mg. Findings through week 24 were previously reported; those through week 104 are presented herein.ResultsAt week 104, 38.5%, 60.1% and 71.4% of patients in groups 1, 2 and 3, respectively, had at least 20% improvement in the Assessment in SpondyloArthritis international Society response criteria (ASAS20); 38.5%, 55.8% and 54.3% had an ASAS40 response and 21.8%, 31.9% and 30.7% were in ASAS partial remission. Mean Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores were <3 at week 104 for all the treatment regimens. Golimumab safety through week 104 was similar to that through week 24.ConclusionClinical response that was achieved by patients receiving golimumab through 24 weeks was sustained through 52 and 104 weeks. The golimumab safety profile appeared to be consistent with the known safety profile of tumour necrosis factor inhibitors.

Download Full-text

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.145946 ◽

2011 ◽

Vol 70 (6) ◽

pp. 1108-1110 ◽

Cited By ~ 119

Author(s):

I-H Song ◽

F Heldmann ◽

M Rudwaleit ◽

H Haibel ◽

A Weiß ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Pilot Study ◽

Activity Index ◽

Disease Activity Index ◽

Inadequate Response ◽

Open Label ◽

Tnfα Inhibitor ◽

Group 2 ◽

Activity Index Score ◽

Group 1

ObjectiveTo prospectively explore the short-term efficacy and safety of abatacept in patients with ankylosing spondylitis (AS).MethodsIn this prospective open-label pilot study, abatacept (10 mg/kg) was administered intravenously on days 1, 15, 29 and every 28 days thereafter up to week 24 in 15 tumour necrosis factor α (TNFα)-inhibitor naive patients (group 1) and 15 patients with inadequate response to TNFα inhibitors (group 2) with active AS. The primary end point was the proportion of patients with 40% improvement according to the Assessment of SpondyloArthritis international Society criteria (ASAS40) in both groups at week 24.ResultsAt week 24, ASAS40 was reached by 13% of group 1 and 0% of group 2; 20% improvement (ASAS20) was reached by 27% and 20%, respectively. There was no significant change of Bath Ankylosing Spondylitis Disease Activity Index score, patient global assessment or C reactive protein. Overall, abatacept was well tolerated.ConclusionsIn this pilot open-label AS study a major response was not observed.

Download Full-text

Time course of changes in the clinical and instrumental manifestations of coxitis in patients with ankylosing spondylitis during golimumab therapy: a GO-COX study. Preliminary results

Rheumatology Science and Practice ◽

10.14412/1995-4484-2019-307-311 ◽

2019 ◽

Vol 57 (3) ◽

pp. 307-311 ◽

Cited By ~ 1

Author(s):

Sh. Erdes ◽

T. V. Dubinina ◽

E. M. Agafonova ◽

D. G. Rumyantseva ◽

S. Yu. Davidyan ◽

...

Keyword(s):

New York ◽

Ankylosing Spondylitis ◽

Disease Activity ◽

Time Course ◽

Activity Index ◽

Disease Activity Index ◽

Biologic Agent ◽

Multicenter Cohort Study ◽

Bone Edema

Objective: to evaluate the effect of golimumab (GLM) on the clinical, functional, and instrumental manifestations of coxitis in ankylosing spondylitis (AS).Subjects and methods. The non-interventional prospective multicenter cohort study GO-COX conducted in the medical centers of the Russian Federation enrolled 39 patients with AS (meeting the modified New York criteria) and coxitis with BASRI-hip score 0–2, who were prescribed GLM as the first biologic agent at a dose of 50 mg per month. The patient's health status was assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) before and at 6 and 12 months after GLM treatment initiation. Based on the data of radiographs (the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-hip) scoring system), ultrasonography (USG), and STIR and T1 magnetic resonance imaging (MRI), the investigators assessed the manifestations of coxitis. The planned follow-up duration was 2 years. This paper includes 12-month follow-up results in 22 patients.Results and discussion. At 12 weeks of GLM therapy, there were significant positive index changes: a decrease in BASDAI by an average of 3.28±1.62, in ASDAS-CRP by 2.20±0.95, in BASFI by 2.52±2.09, and in BASMI by 1.41±1.50 (p<0.0001). One year after GLM therapy initiation, the BASRI-hip values remained unchanged; 40 to 60% of patients had no MRI and USG signs of coxitis.Conclusion. At 12 weeks, GLM therapy in patients with AS and coxitis provided a reduction in the clinical and instrumental signs of coxitis, as evidenced by MRI and USG (a significant decline in the proportion of patients with subchondral bone edema and intraarticular effusion), and also effectively suppressed other manifestations of inflammatory activity.

Download Full-text

Efficiency of drug therapy for coxitis in patients with ankylosing spondylitis according to the data of a 12-month prospective follow-up

Rheumatology Science and Practice ◽

10.14412/1995-4484-2018-727-730 ◽

2019 ◽

Vol 56 (6) ◽

pp. 727-730

Author(s):

A. V. Petrov ◽

V. A. Beloglazov ◽

Yu. O. Shevnina ◽

A. A. Petrov

Keyword(s):

Ankylosing Spondylitis ◽

Disease Activity ◽

Synovial Membrane ◽

Time Course ◽

Structural Changes ◽

Activity Index ◽

Disease Activity Index ◽

Membrane Thickness ◽

Group 2 ◽

Factor Α

Hip joint (HJ) inflammation in ankylosing spondylitis (AS) is a frequent manifestation and an unfavorable prognostic feature of the disease and it requires total hip arthroplasty in 7–8% of patients. Nonsteroidal anti-inflammatory drugs (NSAIDs), sulfasalazine (SSZ), and tumor necrosis factor-α inhibitors are used to treat AS-associated coxitis. However, the influence of these treatments on the time course of HJ structural changes has not been currently studied.Objective: to estimate the time course of HJ changes clinical, X-ray, and ultrasonographic examination was performed in AS patients receiving various drugs: NSAIDs, SSZ, and adalimumab (ADA) during 12 months.Subjects and methods. Seventy-eight AS patients who had clinical, ultrasonographic, and radiological signs of HJ inflammation were followed up. The patients were divided into three groups: 1) 25 patients who took NSAIDs daily; 2) 26 patients who received NSAIDs and SSZ in a daily dose of 2–3 g; 3) 27 patients who were treated with NSAIDs and subcutaneous injections of ADA 40 mg once every 2 weeks. In addition to conventional clinical and laboratory investigations, all the patients underwent radiography with Bath Ankylosing Spondylitis Radiology HIP Index (BASRI-Hip) estimation and HJ ultrasonography.Results and discussion. In Group 2, 12-month SSZ use led to a reduction in median pain intensity during HJ movements on a visual analog scale (VAS) from 26.1 [13.9; 42.7] to 69.3 [56.8; 79.3] mm (p<0.05), CRP levels from 4.4 [1.5; 6.9] to 15.2 [8.3; 21.8] mg/l (p<0.05), and synovial membrane thickness from 6.7 [5.8; 8.5] to 9.6 [7.9; 11.8] mm (p<0.05) compared to the basic data. In Group 3, ADA administration resulted in pain reduction from 14.2 [5.2; 26.7] to 72.1 [65.3; 89.1] mm (p<0.05), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) from 1.7 [1.1; 3.1] and 1.4 [1.1; 2.2] to 7.5 [5.9; 8.6] and 3.1 [2.6; 3.9], respectively (p<0.05), CRP levels from 2.7 [0.2; 5.8] to 24.3 [17.4; 35.9] mg/l (p<0.05), and HJ synovial membrane thickness from 6.3 [5.0; 7.7] to 9.9 [8.1; 12.6] mm (p<0.05). SSZ and ADA did not substantially affect the time course of changes in BASRI-Hip and the process of new osteophyte formation in HJ.Conclusion. The use of SSZ and ADA in the complex treatment of patients with AS-associated coxitis leads to a lower HJ synovitis activity.

Download Full-text